CRL (Charles River Laboratories International) Change In Receivables : $44 Mil (TTM As of Sep. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Charles River Laboratories International Change In Receivables?

Charles River Laboratories International's change in receivables for the quarter that ended in Sep. 2024 was $17 Mil. It means Charles River Laboratories International's Accounts Receivable declined by $17 Mil from Jun. 2024 to Sep. 2024 .

Charles River Laboratories International's change in receivables for the fiscal year that ended in Dec. 2023 was $-33 Mil. It means Charles River Laboratories International's Accounts Receivable increased by $33 Mil from Dec. 2022 to Dec. 2023 .

Charles River Laboratories International's Accounts Receivable for the quarter that ended in Sep. 2024 was $558 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Charles River Laboratories International's Days Sales Outstanding for the three months ended in Sep. 2024 was 50.40.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Charles River Laboratories International's liquidation value for the three months ended in Sep. 2024 was $-3,380 Mil.

Charles River Laboratories International Change In Receivables Historical Data

The historical data trend for Charles River Laboratories International's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Charles River Laboratories International Change In Receivables Chart

Charles River Laboratories International Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-8.32

-85.63

-26.63

-150.57

-33.43

Charles River Laboratories International Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Receivables	Get a 7-Day Free Trial															-10.83	25.65	-17.28	18.35	17.23

Charles River Laboratories International Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $44 Mil.

Charles River Laboratories International (NYSE:CRL) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Charles River Laboratories International's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	557.761	/	1009.763	*	91
=	50.40

2. In Ben Graham's calculation of liquidation value, Charles River Laboratories International's accounts receivable are only considered to be worth 75% of book value:

Charles River Laboratories International's liquidation value for the quarter that ended in Sep. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	210.171	-	4176.125	+	0.75 * 557.761	+	0.5 * 336.2
=	-3,380

Charles River Laboratories International Change In Receivables Related Terms

Thank you for viewing the detailed overview of Charles River Laboratories International's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Charles River Laboratories International Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Charles River Laboratories International Inc (NYSE:CRL) » Definitions » Change In Receivables

Comparable Companies

EXAS MEDP QGEN RVTY RDNT GH SHC NEOG VCYT TWST TMO DHR XSWX:LONN A IQV IDXX MTD ILMN WAT NTRA

Traded in Other Exchanges

RV6:Germany RV6:Germany

Address

251 Ballardvale Street, Wilmington, MA, USA, 01887

Website

https://www.criver.com

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Executives

Richard F Wallman	director	HONEYWELL, 101 COLUMBIA ROAD, MORRISTOWN NJ 07962
Joseph W Laplume	officer: EVP, Corp Strategy & Develop	251 BALLARDVALE STREET, WILMINGTON MA 01887
James C Foster	director, officer: President and CEO	251 BALLARDVALE ST, WILMINGTON MA 01887
George Massaro	director
Michael Gunnar Knell	officer: CSVP&Chief Accounting Officer	BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Victoria L Creamer	officer: EVP & Chief People Officer	164 PINE HILL ROAD, NEW FAIRFIELD CT 06812
William D Barbo	officer: Corporate Executive VP & CCO	251 BALLARDVALE STREET, WILMINGTON MA 01887
Shannon M Parisotto	officer: CEVP, Disc & Safety Assessment	251 BALLARDVALE ST, WILMINGTON MA 01887
Birgit Girshick	officer: Corporate Executive VP	251 BALLARDVALE STREET, WILMINGTON MA 01887
Flavia Pease	officer: Corporate Executive VP	251 BALLARDVALE STREET, WILMINGTON MA 01887
David Ross Smith	officer: Corporate Executive VP & CFO	251 BALLARDVALE STREET, WILMINGTON MA 01887
Deborah Turner Kochevar	director	251 BALLARDVALE STREET, WILMINGTON MA 01887
Milne George M Jr	director
Stephen D Chubb	director	C/O MATRITECH INC, 330 NEVADA STREET, NEWTON MA 02460
George Llado	director	251 BALLARDVALE STREET, WILMINGTON MA 01887